This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
PRIMARY OBJECTIVES: I. To evaluate the feasibility of 68-Ga RM2 PET/MRI for identification of estrogen receptor positive primary breast cancer and metastases OUTLINE: Patients receive 68-Ga-RM2 intravenously (IV) and after 45 minutes undergo PET/MRI over 30-60 minutes. After completion of study, patients are followed up at 24-72 hours, and then for 12 months.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
5
Given IV
Undergo PET/MRI
Undergo PET/MRI
Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
Detection of ER Positive Breast Cancer and Metastases on 68-Ga RM2 PET/MRI
Number of lesions identified on 68-Ga RM2 positron emission tomography/magnetic resonance imaging (PET/MRI). The outcome will be reported as the number of participants with successful PET based detection of estrogen receptor (ER) positive breast cancer and metastases.
Time frame: up to 2 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
General Electric (GE) Healthcare non-approved PET scanner coils and software